U.S. Markets open in 6 hrs 33 mins
  • S&P Futures

    4,249.50
    +3.75 (+0.09%)
     
  • Dow Futures

    34,488.00
    +26.00 (+0.08%)
     
  • Nasdaq Futures

    14,014.50
    +20.25 (+0.14%)
     
  • Russell 2000 Futures

    2,332.50
    +2.00 (+0.09%)
     
  • Crude Oil

    71.35
    +0.44 (+0.62%)
     
  • Gold

    1,861.70
    -17.90 (-0.95%)
     
  • Silver

    27.92
    -0.23 (-0.80%)
     
  • EUR/USD

    1.2108
    +0.0001 (+0.0121%)
     
  • 10-Yr Bond

    1.4620
    0.0000 (0.00%)
     
  • Vix

    15.65
    -0.45 (-2.80%)
     
  • GBP/USD

    1.4114
    -0.0002 (-0.0169%)
     
  • USD/JPY

    109.6800
    +0.0450 (+0.0410%)
     
  • BTC-USD

    39,601.23
    +4,415.63 (+12.55%)
     
  • CMC Crypto 200

    986.37
    +44.56 (+4.73%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Seelos Therapeutics to Participate in the 33rd Annual Roth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33rd Annual Roth Conference, which will be held virtually on March 15-17, 2021.

(PRNewsfoto/Seelos Therapeutics, Inc.)
(PRNewsfoto/Seelos Therapeutics, Inc.)

Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings via conference calls on March 16th and 17th.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-33rd-annual-roth-conference-301229245.html

SOURCE Seelos Therapeutics, Inc.